🔎 Trials Near Me

Hem › Lupus › Texas › Houston

Kliniska studier för Lupus i Houston, TX

13 studier för Lupus söker deltagare vid platser i och runt Houston (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.

Officiell studietext (engelska)

Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

RekryterarFas 3
  • Sl0044 50696, Houston
  • Sl0044 50723, Houston
  • Sl0044 50738, Bellaire · 7 mi bort
Ålder 16 och äldre · Alla kön · Uppdaterad 2 okt. 2026 · NCT06617325

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

RekryterarFas 2
  • Prolato Clinical Research Center, Houston
Ålder 18 till 100 · Alla kön · Uppdaterad 1 okt. 2026 · NCT05268289

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

RekryterarFas 2
  • The University of Texas Health Science Center at Houston, Houston
Ålder 18 till 74 · Alla kön · Uppdaterad 1 okt. 2026 · NCT07409181

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

RekryterarFas 3
  • Novel Research LLC, Bellaire · 7 mi bort
Ålder 12 till 100 · Alla kön · Uppdaterad 1 okt. 2026 · NCT06133972

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

RekryterarFas 3
  • Research Site, Houston
Ålder 5 till 17 · Alla kön · Uppdaterad 30 sep. 2026 · NCT05835310

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

RekryterarFas 3
  • Research Site, Houston
Ålder 18 till 70 · Alla kön · Uppdaterad 25 sep. 2026 · NCT07430306

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

RekryterarFas 1
  • UT MD Anderson Cancer Center, Houston
Ålder 18 och äldre · Alla kön · Uppdaterad 23 sep. 2026 · NCT03816345

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis

RekryterarFas 1
  • Baylor College of Medicine, Houston
Ålder 18 till 60 · Alla kön · Uppdaterad 14 sep. 2026 · NCT06975787

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

RekryterarFas 3
  • Accurate Clinical Research, Humble · 17 mi bort
Ålder 18 till 75 · Alla kön · Uppdaterad 14 sep. 2026 · NCT07355218

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

RekryterarFas 1/2
  • University of Texas MD Anderson Cancer Center, Houston
Ålder 18 till 65 · Alla kön · Uppdaterad 26 aug. 2026 · NCT06121297

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

RekryterarFas 3
  • Novel Research, LLC., Houston
  • Northwest Houston Arthritis, Houston
  • Rheumatology Care Center, PLLC, Bellaire · 7 mi bort
Ålder 18 till 75 · Alla kön · Uppdaterad 30 juli 2026 · NCT07201129

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

RekryterarObservationsstudie
  • M D Anderson Cancer Center, Houston
Ålder 18 och äldre · Alla kön · Uppdaterad 20 maj 2026 · NCT04751396

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

RekryterarFas 1/2
  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
Ålder 18 och äldre · Alla kön · Uppdaterad 15 apr. 2026 · NCT06434363

Lupus-studier i andra städer

Andra studier i Houston

Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.